TG Therapeutics, Inc. (LON:0VGI)

TG Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	329	233.66	2.79	6.69	0.15
Revenue Growth (YoY)	40.80%	8290.02%	-58.36%	4300.66%	-
Cost of Revenue	38.49	14.13	0.27	0.79	-
Gross Profit	290.52	219.53	2.52	5.9	0.15
Selling, General & Admin	154.3	122.71	95.48	128.09	107.85
Research & Development	94.29	76.19	125.35	222.58	165.9
Operating Expenses	248.59	198.9	220.84	350.67	273.75
Operating Income	41.93	20.63	-218.32	-344.77	-273.59
Interest Expense	-24.03	-12.62	-10.19	-5.64	-6.33
Other Non Operating Income (Expenses)	7.69	5.04	4.7	2.31	0.54
Pretax Income	25.59	13.06	-223.81	-348.1	-279.38
Income Tax Expense	2.21	0.39	-	-	-
Net Income	23.38	12.67	-223.81	-348.1	-279.38
Net Income to Common	23.38	12.67	-223.81	-348.1	-279.38
Net Income Growth	84.52%	-	-	-	-
Shares Outstanding (Basic)	145	142	135	132	115
Shares Outstanding (Diluted)	160	149	135	132	115
Shares Change (YoY)	7.96%	9.67%	2.41%	14.64%	30.51%
EPS (Basic)	0.16	0.09	-1.65	-2.63	-2.42
EPS (Diluted)	0.15	0.09	-1.65	-2.63	-2.42
EPS Growth	68.03%	-	-	-	-
Free Cash Flow	-40.56	-31.41	-176.18	-296.04	-214.86
Free Cash Flow Per Share	-0.25	-0.21	-1.30	-2.24	-1.86
Gross Margin	88.30%	93.95%	90.48%	88.19%	100.00%
Operating Margin	12.74%	8.83%	-7838.99%	-5154.28%	-179996.05%
Profit Margin	7.11%	5.42%	-8036.34%	-5204.08%	-183803.29%
Free Cash Flow Margin	-12.33%	-13.44%	-6326.18%	-4425.70%	-141357.90%
EBITDA	42	20.84	-218.01	-344.49	-273.44
EBITDA Margin	12.77%	8.92%	-	-	-
D&A For EBITDA	0.07	0.21	0.3	0.28	0.16
EBIT	41.93	20.63	-218.32	-344.77	-273.59
EBIT Margin	12.74%	8.83%	-	-	-
Effective Tax Rate	8.64%	2.99%	-	-	-
Revenue as Reported	329	233.66	2.79	6.69	0.15

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.